C
ongenital Central Hypoventilation Syndrome (CCHS) patients characteristically present with diminutive tidal volumes and monotonous respiratory rates asleep and awake, with more profound alveolar hypoventilation typically occurring during sleep (1, 2) . These individuals thus become hypoxemic and hypercarbic, with diminished or absent ventilatory and arousal responses to these endogenous challenges.
Nonetheless, they maintain the ability to consciously alter the rate and depth of breathing. Historically, CCHS was diagnosed in the newborn period, yet we now know that cases can be diagnosed later in infancy, childhood or adulthood (3) (4) (5) (6) (7) (8) (9) (10) (11) . Hirschsprung disease (HSCR) and tumors of neural crest origin present in varied combinations with CCHS, in addition to a spectrum of symptoms compatible with autonomic nervous system dysregulation (ANSD) (1, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . While the spectrum and variability of CCHS-associated symptoms have made diagnosis and treatment complex, these very complexities led to the discovery of its etiology and the consequent successes in diagnosis and treatment. Here we describe some of these discoveries and advances, which over the last five decades have transformed diagnosis, treatment, and quality of life for CCHS patients.
THE EARLY STORY OF CCHS
The 1970 report of an infant with "failure of automatic control of ventilation" (30) was the first to describe the CCHS control of breathing deficit, including extraordinary details regarding the child's autonomic dysregulation. Over the next few years, four additional CCHS patients were reported with clinical courses complicated by cor pulmonale, seizures, neurologic abnormalities and high mortality, but no identifiable neuropathology on autopsy (31, 32) .
Three cases reported by colleagues in 1978 and 1979 (33,34) introduced two important strategies: (i) medical management to prevent or reverse cor pulmonale, and decrease risk for hypoxic encephalopathy, permanent disability or death, and (ii) successful introduction of diaphragm pacing. These infants proved unresponsive to respiratory stimulants, and one developed bilateral ganglioneuroblastomas, suggesting a phenotype not limited to the brainstem. Two of the three cases died before age two, in part due to the cor pulmonale and associated hypoxic encephalopathy, and the third died suddenly and unexpectedly as a young adult.
In 1978, Haddad and colleagues reported three additional CCHS infants (35) . This report highlighted an association Review of CCHS with HSCR and tumors of neural crest origin. The report described an infant who exhibited postnatal cyanosis, improved ventilation in rapid eye movement (REM) sleep, attenuated ventilatory response to hypercarbia, lack of heart rate variability, HSCR and multiple ganglioneuroblastomas. Additionally, this report described CCHS in sisters, the first suggestion that CCHS is familial. While the pathophysiology remained quite unclear, linking CCHS to HSCR and neural crest tumors, and identifying familial recurrence were essential steps in understanding these entities.
In the following decades, additional CCHS cases were reported, though still totaling fewer than 100. These reports, combined with the first large cohort studies appearing in the early 1990s (13) , resulted in a broad understanding of the phenotype and provided hints to the varying organ systems involved, the need for early diagnosis and referral, for vigilant ventilatory management, and for vigorous efforts to support an age-appropriate quality of life. These early cases collectively made it clear that CCHS is far more than a simple orphan disorder of respiratory control. While CCHS-related morbidity and mortality had decreased, major gaps in knowledge remained-in particular, the underlying cause of the disease.
UNCOVERING CLUES TO THE CAUSE: AUTONOMIC DYSFUNCTION AND FAMILIAL RECURRENCE
In response to increasing identification of CCHS, specialized centers were established to advance CCHS care. These centers would aggregate the rare disease patients needed for research analysis, allowing elucidation of CCHS-associated symptoms, uncovering of fundamental systems involved, and defining familial inheritance. Together, these advances would form the basis of future inquiry and discovery.
Dysfunction of the ANS
The effects of the ANS are expansive (Figure 1) , thus diagnosing and delineating symptoms associated with ANSD is complicated, particularly in a rare disease with variable expression. In 1999, the American Thoracic Society published the first official statement on CCHS (1). This statement reported 160-180 known living cases of CCHS, describing symptoms of and conditions associated with CCHS, and recognized critical diagnosis of abnormal respiratory control and related cardiorespiratory and autonomic symptoms. This report expanded the perception of CCHS beyond a control of breathing deficit with asleep hypoventilation, emphasizing that some patients also presented with awake hypoventilation, cardiovascular abnormalities, hypothermia, seizures, neuroblastomas, constipation, HSCR, and ophthalmologic abnormalities. The American Thoracic Society statement encouraged a more integrated view of CCHS symptoms, placing them in context of more general ANSD.
The Hunt for a Gene
Early CCHS reports identified families with disease recurrence, suggesting a hereditary phenomenon (13, (35) (36) (37) , and segregation analyses provided evidence for the inheritance pattern of CCHS that suggested a Mendelian codominant transmission (12, 38) . Thus, researchers began to search for CCHS-causing mutations, focusing primarily on genes implicated in HSCR. While these studies provided interesting candidates for CCHS etiology, results were inconclusive and no single gene emerged as a clear causative factor (39) (40) (41) .
THE BREAKTHROUGH: PHOX2B AS THE DISEASE-DEFINING GENE FOR CCHS

A New Suspect
The Paired-Like Homeobox 2B (PHOX2B) gene encodes a highly conserved homeodomain transcription factor. Early work indicated PHOX2B may play a key role in embryologic development of the ANS, including circuits thought to underlie chemosensory functions (42, 43) . PHOX2B was further implicated in intestinal innervation, linking this gene to the gastrointestinal phenotype as well. Recognizing the overlap in phenotypic manifestations of CCHS with PHOX2B developmental roles, work began to evaluate PHOX2B in CCHS cohorts.
A Link is Identified
In 2003, Amiel and colleagues reported mutations in PHOX2B in 20 of 29 (69%) mainly French CCHS cases (44) . The majority of these mutations (18 of 20) were in-frame expansions of a 20-alanine repeat region found in exon 3 of PHOX2B between 25 and 29 alanines (now termed as polyalanine repeat expansion mutations, PARMs). The two remaining patients had frameshift mutations, part of a group of rarer mutations in PHOX2B now termed non-PARMs (NPARMs). Neither mutation type was found in any controls, nor in parents of the CCHS cases. Similarly, a 2003 report identified PHOX2B PARM and NPARM mutations in 5 of 10 Japanese CCHS cases (41) . These studies implicated PHOX2B in CCHS pathogenesis, but the full story was not yet clear.
25-33 repeats in 21 (88%) and NPARMs in 2 (8%) of 24 CCHS cases. This study confirmed the correlation between PARM length and disease severity. Importantly, this report also demonstrated a technical complication in standard PCR methods that could cause false negative results for PARMs. With this information, the Amiel group (re)analyzed their cohort and identified a PHOX2B mutation in 93% of 174 subjects with CCHS from multiple nations, including 7 of the 9 "mutationnegative" patients reported in 2003 (45) . These, and subsequent studies, confirmed PHOX2B as the disease-defining gene in CCHS (39) .
PHOX2B MUTATIONS AND INHERITANCE
Development of Diagnostic Testing
The 2003 Weese-Mayer report established the first clinically available assay for diagnosis of CCHS, a method for identifying PARM and most frameshift NPARM mutations, together causative in ~95% of CCHS patients (patent donated to Chicago Community Foundation; proceeds support CCHS research) (39) . This test (www.genetests.org; Rush University PHOX2B Screening Test) can be used for prenatal diagnosis and family testing (including detection of low-level mosaicism). Subsequently, many labs began to offer Sequencing PHOX2B in these assays enables diagnosis of all known NPARM and PARM mutations. The disadvantage is sequencing tests often fail to detect lower-level mosaicism (46) , which has been identified both in asymptomatic parents of CCHS cases and rarely in cases with mild CCHS symptoms (unpublished results). Additionally, variations in copy number of PHOX2B (whole and partial gene deletions) have been recently identified in cases with variable, CCHS-like phenotypes (47) . Accordingly, labs now offer PHOX2B deletion/duplication testing. While it is possible that mutations in genes with roles similar to PHOX2B could cause a phenotype similar to CCHS, this has not yet been reported to our knowledge. Consequently, a mutation in PHOX2B is considered requisite to a diagnosis of CCHS (2) . Approximately 1,300 patients with CCHS have been diagnosed since 1970. However, as two studies indicate that the incidence of CCHS is ~1/150,000-1/200,000 live births, it is clear that CCHS remains grossly under-diagnosed (48, 49) . PHOX2B testing has drastically improved CCHS diagnosis, with >80% of known CCHS cases with PARMs now being diagnostically confirmed in the first 60 d of life (unpublished observation).
Delineating Mutation Types
Over 90% of CCHS patients will be heterozygous for an inframe PARM mutation, with the addition of 4-13 alanines to the normal 20 alanine repeat. These mutations produce genotypes of 20/24 to 20/33 (normal genotype is 20/20). Over 100 different NPARM mutations have been identified in nearly 200 patients (2) (unpublished results) including missense, nonsense, frameshift, stop codon and likely splice-site mutations (Figure 2 ). The majority of NPARMs cause very severe forms of CCHS, typically including extensive intestinal aganglionosis and tumors of neural crest origin. However, the protein and cellular effects are varied, with variable expressivity and incomplete penetrance. Indeed, a small subset of these NPARMs have been shown to cause only tumor in one patient, only HSCR in another, and CCHS with or without tumor or HSCR in others, with differences arising even within a single family. Currently, this variability in expression of phenotypes remains poorly defined.
Mosaicism
Parental somatic mosaicism has been confirmed in several large cohorts (11, (50) (51) (52) (53) . The range of mosaicism is estimated to be 9-35% (51) with stable transmission of specific mutations to offspring. Though low level mosaic carriers are not expected to be symptomatic, it is possible that some may present with subclinical phenotypes, and these may worsen with challenges such as respiratory infection, use of respiratory depressants, and generally declining health (51) (personal communication). It is thus recommended that carriers of mosaic PHOX2B mutations undergo careful comprehensive evaluation and follow-up.
Inheritance
Parents of CCHS patients should be tested for PHOX2B mutations, to determine if mosaicism exists (both for family planning and to address possible health risks for mosaic carriers). As low-level mosaicism is difficult to detect using sequencing, a sizing/genotyping test such as the PHOX2B Screening Test is suggested (46) . Germline mosaicism has been identified for PHOX2B mutations (54) . Thus prenatal testing is suggested for individuals with CCHS and all parents of CCHS patients, including both somatic mosaic carriers of PHOX2B mutations, and those who tested negative for somatic mosaicism. Review Weese-Mayer et al.
ADVANCES AT THE BENCH
Uncovering the Molecular Basis of Disease
Since the discovery that PHOX2B was disease-defining for CCHS, work has intensified to uncover both the normal function of PHOX2B and the molecular ramifications of abnormal function. Polyalanine tract expansions, particularly in transcription factors, are a poorly understood but emerging cause of human disease. It is clear that in other polyalanine diseases, as in CCHS, disease severity typically increases with increasing expansion length (55, 56) . Work in animal and cellular models has clarified aspects of the molecular mechanisms of PHOX2B mutations, and the resulting cellular and neurological dysfunction. These results have been augmented by imaging and postmortem autopsy studies in CCHS patients, which have helped to direct bench work in the cell and mouse and evaluate bench results in the human model.
Animal Models
The early knockout mouse model (homozygous null) revealed potential developmental roles for Phox2b that could account for some of the clinical picture seen in CCHS, with deficits throughout respiratory (and autonomic) reflex arcs and including the carotid bodies (57, 58) . A heterozygous null mutant reproduced some of the chemosensory deficit seen in CCHS, but effects were transient (58) . More targeted mutant models did not reproduce the widespread anatomical lesions seen in the knockout mouse, but showed cell loss in a candidate site for central chemosensory function. Knock-in of an analog of the human 20/27 PARM reduced the chemoreflex and produced potentially lethal hypoventilation in neonatal mice (59) . However, restricting the mutation to a pontine cellular lineage reproduced the chemosensory deficit without resulting in lethal hypoventilation (60) . Both manipulations resulted in cell loss in a neural population thought to be crucial to a central chemosensory response, the medullary retrotrapezoid nucleus (RTN) (59, 60) . The RTN, which likely overlaps functionally with a center identified in neonatal mice called the parafacial respiratory group (61, 62) , has become one of the most studied candidates for central chemosensory drive and integration. Evidence for this functional role of the RTN is quite robust in rodent models (63) . First, a subset of Phox2b expressing cells in this region is intrinsically sensitive to extracellular pH (64) . Second, anatomical evidence indicates that the RTN is well-integrated into respiratory neural circuits in a way that would allow integration of afferent input from peripheral chemosensors, efferent connections to respiratory rhythm and pattern circuits, as well as input from neuromodulatory centers (65, 66) . Finally, targeted manipulation of Phox2b-positive cells in the RTN can alter baseline ventilation as well as ventilatory response to hypercapnia in a state-dependent manner (67) (68) (69) . Specifically, the influence of the RTN on respiratory frequency seems to be limited to behavioral states in which medullary respiratory rhythm generators are running relatively autonomously (quiet wakefulness, and non-REM sleep), possibly explaining the more frequent hypoventilation often seen in CCHS patients during these states (70).
Efforts to translate these results to infants have had mixed results. Two studies that attempted to identify the human homolog of the rodent RTN pointed to ponto-medullary regions that were not completely consistent with each other (71, 72) . Autopsy studies in CCHS have indicated damage in other medullary areas as well (13, (73) (74) (75) . Nonetheless, a working hypothesis is that a human homolog of the RTN does exist and plays a crucial role in CCHS pathophysiology. Still, many features of the phenotype may be a result of functional loss of other cell populations and fiber tracts. Imaging studies suggest relatively widespread brain injury in CCHS (76) , and it seems likely that in a subset of cases, the damage may be progressive (though not necessarily due to the disease itself) (77).
Cellular Models
Cellular models have also been developed to evaluate pathogenic mechanisms of PHOX2B mutations. In these models, both PARM and NPARM PHOX2B constructs have demonstrated an impaired ability to transactivate some downstream targets. Mutant PHOX2B PARM constructs have demonstrated an inverse correlation between trans-activating ability and length of the polyalanine expanded tract (78) (79) (80) . In frameshift NPARMs, the impairment was correlated with length of the disrupted C-terminal sequence (78, 79, 81) . These transactivation studies give insight into possible mechanisms of PHOX2B mutations, and offer insight into the basis of the genotype-phenotype relationship.
Localization of both the wild type and expanded PHOX2B proteins, including the possible role of protein aggregation on localization, has also been evaluated. While cell models suggest almost exclusive nuclear localization of the wild type PHOX2B protein, PARMs induced partial or complete cytoplasmic mislocalization and protein aggregation (78, 79) . Longer PARMs were associated with larger protein aggregates in increasing proportions of cells (79) . This finding implicates mutant protein mislocalization as a possible pathogenetic mechanism. In these models, PARMs have also demonstrated a partial dominant negative effect by interfering with normal function of the wild type protein, though this interaction is weak (82) .
Finally, cell models demonstrate DNA binding is reduced for PHOX2B PARM proteins with expansions of 29 alanines and above, with the spontaneous formation of oligomers making them unavailable for DNA binding (78) . Similarly, NPARMs have predominately shown complete loss of DNA binding, despite correct nuclear localization (78, 79) . PHOX2B NPARM constructs retain their ability to suppress cellular proliferation, without promoting differentiation, suggesting a mechanism which might promote development of neural crest tumors (83) and explain the high prevalence of neuroblastoma in NPARM patients.
The ability to replicate PARM and NPARM pathogenic mechanisms in cell models holds great potential for developing therapeutic interventions. Indeed, experiments in these models have allowed in vitro analysis to screen several molecules for effects on promotion of nuclear localization of PHOX2B and recovery of the protein's transactivation potential (81, 84) .
A recent study of two postmortem CCHS cases (one PARM and one NPARM) (87) reported neuronal loss within the locus coeruleus, the major noradrenergic nucleus of the brain, connected to systemic arousal and sympathetic activation (88) . The same study used a transgenic mouse model to evaluate timing of developmental defects and to confirm that expression of this NPARM leads to deleterious effects in the locus coeruleus (though a previous study did not find deleterious effects on the locus coeruleus with the 20/27 PARM mutation (59)). Since the PHOX2A gene is required for development of the locus coeruleus and interacts with PHOX2B, it has been suggested that PHOX2B mutations may cause a dominant-negative effect on PHOX2A. The results from cellular models have indicated that PHOX2B mutants do not interfere with the localization and transcriptional activity of PHOX2A, but did identify an unexpected synergistic effect through PHOX2A and PHOX2B mutation heterodimer formation (82) . These studies highlight the collective advances made possible by studying PHOX2B mutations in human, animal, and cellular models.
ADVANCES AT THE BEDSIDE
With PHOX2B established as the disease-defining gene for CCHS and early analysis indicating a relationship between specific PHOX2B mutations and CCHS phenotypes, the opportunity for better understanding of CCHS and anticipatory management emerged.
Genotype-Based Anticipatory Management
Among individuals with PARMs, a relationship has been identified for physiologic ANSD that includes artificial ventilatory needs, risk of cardiac sinus pauses, heart rate variability, and a number of symptoms of ANSD (2, 3, 39, 50) . Knowledge of genotype provides a benchmark for the medical team in providing optimal life support and evaluation from diagnosis onward, with the aim of optimizing outcome ( Table 1) Sinus pause. Children with the 20/27 genotype are very likely to have ≥3 second pauses (>80%), those with 20/25 genotype are very unlikely to have such pauses in childhood (0%) (25) , and the children with the 20/26 genotype often have an intermediate sinus pause frequency (~20%). Introduction of 72-hour Holter recordings every 12 mo at a minimum has allowed for early identification of these sinus pauses permitting timely cardiac pacemaker placement. Heart rate variability is characteristically decreased in CCHS (27) due to a decrease in cardiac baroreflex sensitivity and blunted sympathetic response (8, 23) . A recent report demonstrated a genotype-phenotype relationship for heart rate variability during exogenous ventilatory response testing, enabling assessment of risk for sinus pauses (29) .
Anatomic ANSD. Amongst PARMs, evaluation for HSCR is based on clinical symptoms in recognition of overall risk of 20% across the 20/26-20/33 genotypes. PHOX2B mutations in mouse models exhibit sympathetic agangliogenesis, displaying decreased proliferation of neural crest-derived cells and development of gastrointestinal glia cells (89) . Even in cases without HSCR diagnosis, cases display symptoms of lower esophageal dysfunction and intestinal dysmotility that result in symptoms such as severe constipation and abnormal esophageal motility (15). Risk of a tumor of neural crest origin is <2% overall, and even then only among the longer PARMs. However, overall risk for HSCR and/or neuroblastoma in NPARMS is >50%. Screening for neural crest tumors is advised in children with 20/28-20/33 genotypes (in addition to all children with NPARMs). Though the rare tumors are expected to be ganglioneuromas or ganglioneuroblastomas in the PARMs, a neuroblastoma was reported in a child with the 20/33 genotype (90).
Identifying Late-onset CCHS
Late-onset CCHS patients typically have a PARM (20/24 or 20/25) and present after 1 mo of age. A few children with an NPARM will present late as well. This later presentation reflects the variable penetrance of these mutations and potential need for an environmental cofactor. Late-onset CCHS should be considered among individuals with unexplained centrally mediated hypoventilation and/or cyanosis or seizures with sedation or anesthesia, recurrent severe pulmonic infection with difficulty weaning from ventilatory support, obstructive sleep apnea refractory to intervention, or unexplained neurocognitive impairment. With a heightened level of suspicion, increasing numbers of older children and adults have been diagnosed with late-onset CCHS and properly treated (2, 7, 51) .
Optimizing Neurocognitive Performance
Impaired oxygen delivery to the brain, whether acute or chronic, can have detrimental effects on neurocognitive development. Individuals with CCHS require assisted ventilation, but the optimum method can include positive pressure ventilation via tracheostomy, bi-level positive airway pressure via mask, negative pressure ventilation and diaphragm pacing. The American Thoracic Society statement recommends positive pressure ventilation via tracheostomy in the first several years of life to ensure optimal oxygenation and ventilation (1, 2) . The method of choice in later years will depend on a variety of factors including severity of disease, patient age, level of patient and family cooperation, availability and quality of home health care, amongst other factors. The level of oxygen stability obtained with each varies. Thus, the method of respiratory assistance is likely to play a factor in neurocognitive outcome. Past literature has indicated deficiencies of mental abilities in school-age children with CCHS (91) (92) (93) (94) . Even in preschool years, children with CCHS demonstrate reduced neurocognitive performance (95) . In these cases, PHOX2B genotype was clearly associated with both mental and motor outcome ( Table 2 ). This association was also found with CCHS-related features such as severe cyanotic breath holding spells, sinus pauses, seizures, and severity of hypoventilation ( Table 3) . It is unclear if this association is intrinsic to the specific mutation, the phenotypes associated with the mutation, or most likely both. Despite the delays observed, 29% of subjects had mid-average mental development scores, and 13% performed above that level. These findings suggest the potential for excellent neurocognitive outcome. This potential appears greatest in individuals with a 20/25 genotype in this cohort where average Bayley mental scores were over the population mean of 100. In sharp contrast, a 2015 report identified remarkably low IQs in a cohort of 19 Japanese children with the 20/25 genotype, with 42% of these cases reported as having displayed "mental retardation" (48) . Many of these 20/25 genotype Japanese patients were diagnosed after the first month of life and some were managed with minimal support including home oxygen only, despite clear recommendations against such support (1,2). While it is not possible to directly compare the cohorts and determine if the dramatic differences are due to standard of care, age at diagnosis, genetic background, testing methods employed, or other, it seems clear given the disparity in outcome within the same genotype, that early recognition and conservative management are essential to insuring optimized neurocognitive outcome. Recognizing this, neurodevelopmental monitoring would be most beneficial beginning in early infancy. (96, 97) . While the seeming neurodevelopmental primacy of PHOX2B has discouraged speculation about fundamental interventions, hope can be found in anatomical evidence that a brainstem nucleus (area postrema) may be affected by PHOX2B mutations but may also undergo significant postnatal development (98) . Together with recent evidence that the respiratory control phenotype in CCHS may be preserved in some patients early in life (29) (Figure 3) , these results suggest there may be a substrate for intervention in the fundamental pathological processes of CCHS even after birth. Before PHOX2B was identified as the disease-defining gene in CCHS, diagnosis was often delayed, introduction of artificial ventilation was variable and often inadequate, leading to high risk for neurocognitive impairment, prolonged hospitalization, and early death. In sharp contrast, knowledge of the role of PHOX2B in the disease has enabled today's physician to confirm CCHS with diagnostic testing in the first weeks of life, initiate early and aggressive artificial ventilation, and anticipate management pertinent to sinus pauses, HSCR, risk for neural crest tumors, ANSD and severity of hypoventilation. While life expectancy for patients identified since the discovery of PHOX2B as the disease-defining gene and development of CCHS diagnostic testing in 2003 remains unclear, the majority of CCHS patients are now living well into adulthood with drastically improved neurocognitive outcome.
In summary, the "bedside-to-bench" CCHS research journey has taken this rare neurocristopathy to the forefront of genetics and neurobiology of autonomic control overall. Study of CCHS and the discovery of the role of PHOX2B have enabled new insights into development and control of central respiratory drive, chemosensation, and autonomic function, and may yield new insights into more common disorders such as sudden infant death syndrome and ventilatory instability in premature infants. This remarkable journey to understand and effectively treat this rare disease has fostered an entire scientific discipline studying control of breathing, autonomic regulation, and neurocristopathies. The vision for the next leg of this journey is continued integration of new knowledge, building on the discoveries of the past 50 y to further advance CCHS clinical care. 
